Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors. [electronic resource]
Producer: 20000424Description: 227-31 p. digitalISSN:- 0015-5500
- Animals
- CD4-Positive T-Lymphocytes -- immunology
- Cancer Vaccines -- therapeutic use
- Carcinoma -- immunology
- Combined Modality Therapy
- Cross Reactions
- Cytotoxicity Tests, Immunologic
- DNA, Complementary -- genetics
- Disease Progression
- Genetic Therapy
- Immunotherapy, Active
- Interleukin-2 -- genetics
- Killer Cells, Natural -- immunology
- Mice
- Mice, Inbred C57BL
- Neoplasm Recurrence, Local -- prevention & control
- Neoplasm Transplantation
- Neoplasm, Residual
- Recombinant Fusion Proteins -- physiology
- Sarcoma, Experimental -- metabolism
- Spleen -- immunology
- T-Lymphocytes, Cytotoxic -- immunology
- Transfection
- Tumor Cells, Cultured -- immunology
- Vaccination
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.